Risk factors and reasons for romosozumab nonadherence in a case-control study

Abstract Risk factors and reasons for romosozumab nonadherence remain unclear. This study compared patients who adhered to romosozumab therapy with those who did not to identify possible risk factors and reasons for treatment nonadherence. This case-control study included all eligible patients diagn...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting-Chien Tsai, Yun-Shan Yen, Chang-Hao Lin, Ya-Chi Cheng, Yu-Sian Ding, Chen-Hao Chiang, Cheng-Yi Wu
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-04595-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849335246091190272
author Ting-Chien Tsai
Yun-Shan Yen
Chang-Hao Lin
Ya-Chi Cheng
Yu-Sian Ding
Chen-Hao Chiang
Cheng-Yi Wu
author_facet Ting-Chien Tsai
Yun-Shan Yen
Chang-Hao Lin
Ya-Chi Cheng
Yu-Sian Ding
Chen-Hao Chiang
Cheng-Yi Wu
author_sort Ting-Chien Tsai
collection DOAJ
description Abstract Risk factors and reasons for romosozumab nonadherence remain unclear. This study compared patients who adhered to romosozumab therapy with those who did not to identify possible risk factors and reasons for treatment nonadherence. This case-control study included all eligible patients diagnosed with osteoporosis who received romosozumab therapy at our hospital between February 2022 and March 2024. The patients were divided into adherence and nonadherent groups. Nonadherence was defined as failure to follow the monthly injection schedule for 12 injections over a one-year period, without transitioning to other antiosteoporotic medications. Relevant data were retrospectively collected from the patients’ medical records. Univariate and logistic regression analyses were performed to identify the associations of patient characteristics with romosozumab nonadherence. A subgroup analysis was performed to identify the associations between the reasons for nonadherence and the type of payment for romosozumab therapy. The adherence and nonadherent groups comprised 62 and 69 patients, respectively. Male patients had a 9.03-fold higher risk of nonadherence than did female patients (P = .041). Self-payment for medications was associated with a 2.756-fold higher risk of nonadherence than was receiving a full subsidy (P = .024). The most common reasons for nonadherence were patient-related factors (87.0%, 60 of the 69 patients in the nonadherent group), followed by medicine-related factors (8.7%, 6 patients) and health system–related factors (4.3%, 3 patients). Male sex and self-payment for medications are risk factors for romosozumab nonadherence. Patient-related factors appear to be the most common reasons for nonadherence. These results can aid healthcare providers in implementing appropriate interventions.
format Article
id doaj-art-d4441ff3f531456ca9c65c0f1251fcc7
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-d4441ff3f531456ca9c65c0f1251fcc72025-08-20T03:45:20ZengNature PortfolioScientific Reports2045-23222025-07-011511910.1038/s41598-025-04595-zRisk factors and reasons for romosozumab nonadherence in a case-control studyTing-Chien Tsai0Yun-Shan Yen1Chang-Hao Lin2Ya-Chi Cheng3Yu-Sian Ding4Chen-Hao Chiang5Cheng-Yi Wu6Department of Orthopaedics, Ditmanson Medical Foundation Chia-Yi Christian HospitalDepartment of Rehabilitation, Just Swing Rehab ClinicDepartment of Orthopaedics, Ditmanson Medical Foundation Chia-Yi Christian HospitalDivision of Family Medicine, Ditmanson Medical Foundation Chia-Yi Christian HospitalDepartment of Orthopaedics, Ditmanson Medical Foundation Chia-Yi Christian HospitalDepartment of Orthopaedics, Ditmanson Medical Foundation Chia-Yi Christian HospitalDepartment of Rehabilitation, Just Swing Rehab ClinicAbstract Risk factors and reasons for romosozumab nonadherence remain unclear. This study compared patients who adhered to romosozumab therapy with those who did not to identify possible risk factors and reasons for treatment nonadherence. This case-control study included all eligible patients diagnosed with osteoporosis who received romosozumab therapy at our hospital between February 2022 and March 2024. The patients were divided into adherence and nonadherent groups. Nonadherence was defined as failure to follow the monthly injection schedule for 12 injections over a one-year period, without transitioning to other antiosteoporotic medications. Relevant data were retrospectively collected from the patients’ medical records. Univariate and logistic regression analyses were performed to identify the associations of patient characteristics with romosozumab nonadherence. A subgroup analysis was performed to identify the associations between the reasons for nonadherence and the type of payment for romosozumab therapy. The adherence and nonadherent groups comprised 62 and 69 patients, respectively. Male patients had a 9.03-fold higher risk of nonadherence than did female patients (P = .041). Self-payment for medications was associated with a 2.756-fold higher risk of nonadherence than was receiving a full subsidy (P = .024). The most common reasons for nonadherence were patient-related factors (87.0%, 60 of the 69 patients in the nonadherent group), followed by medicine-related factors (8.7%, 6 patients) and health system–related factors (4.3%, 3 patients). Male sex and self-payment for medications are risk factors for romosozumab nonadherence. Patient-related factors appear to be the most common reasons for nonadherence. These results can aid healthcare providers in implementing appropriate interventions.https://doi.org/10.1038/s41598-025-04595-zMedication adherenceOsteoporosisPatient complianceRisk factors
spellingShingle Ting-Chien Tsai
Yun-Shan Yen
Chang-Hao Lin
Ya-Chi Cheng
Yu-Sian Ding
Chen-Hao Chiang
Cheng-Yi Wu
Risk factors and reasons for romosozumab nonadherence in a case-control study
Scientific Reports
Medication adherence
Osteoporosis
Patient compliance
Risk factors
title Risk factors and reasons for romosozumab nonadherence in a case-control study
title_full Risk factors and reasons for romosozumab nonadherence in a case-control study
title_fullStr Risk factors and reasons for romosozumab nonadherence in a case-control study
title_full_unstemmed Risk factors and reasons for romosozumab nonadherence in a case-control study
title_short Risk factors and reasons for romosozumab nonadherence in a case-control study
title_sort risk factors and reasons for romosozumab nonadherence in a case control study
topic Medication adherence
Osteoporosis
Patient compliance
Risk factors
url https://doi.org/10.1038/s41598-025-04595-z
work_keys_str_mv AT tingchientsai riskfactorsandreasonsforromosozumabnonadherenceinacasecontrolstudy
AT yunshanyen riskfactorsandreasonsforromosozumabnonadherenceinacasecontrolstudy
AT changhaolin riskfactorsandreasonsforromosozumabnonadherenceinacasecontrolstudy
AT yachicheng riskfactorsandreasonsforromosozumabnonadherenceinacasecontrolstudy
AT yusianding riskfactorsandreasonsforromosozumabnonadherenceinacasecontrolstudy
AT chenhaochiang riskfactorsandreasonsforromosozumabnonadherenceinacasecontrolstudy
AT chengyiwu riskfactorsandreasonsforromosozumabnonadherenceinacasecontrolstudy